Please assess the completion status of the following clinical trial:

Trial Title: THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs)~* Healthy female subjects and/or male subjects of African-American/Black or Caucasian race~Exclusion Criteria:~* History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males~* Treatment with an investigational drug within 30 days~* Screening supine blood pressure \<90 or \>/=140 mm Hg (systolic) or \<60 or \>/= 90 mm Hg (diastolic), following at least 5 minutes of supine rest~* Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.~* Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day~* Subjects who have a CYP3A4\*22 allele and/or have a SLCO1B1 \*5 or \*15 allele

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): African-Americans with No CYP3A5\*1 alleles (poor metabolizer)
- Cohort 2 (Type: EXPERIMENTAL): African-Americans with One CYP3A5\*1 allele (intermediate metabolizer)
- Cohort 3 (Type: EXPERIMENTAL): African-Americans with Two CYP3A5\*1 alleles (extensive metabolizer)
- Cohort 4 (Type: EXPERIMENTAL): Caucasians with No CYP3A5\*1 alleles (poor metabolizer)

Based on this trial design, predict the completion outcome and termination type (if applicable).